Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
TBD Bevacizumab Cancelled
Tecartus brexucabtagene autoleucel Mantle cell lymphoma Reimburse with clinical criteria and/or conditions Complete
Tecartus brexucabtagene autoleucel Acute lymphoblastic leukemia Reimburse with clinical criteria and/or conditions Complete
Tecentriq Atezolizumab Withdrawn
Tecentriq Atezolizumab Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Reimburse with clinical criteria and/or conditions Complete
Tecentriq Atezolizumab Small Cell Lung Cancer (SCLC) Do not reimburse Complete
Tecentriq atezolizumab Non-small cell lung cancer Reimburse with clinical criteria and/or conditions Complete
Tecentriq atezolizumab Small Cell Lung Cancer Reimburse with clinical criteria and/or conditions Complete
Tecentriq & Avastin Atezolizumab & Bevacizumab NSQ-NSCLC Do not reimburse Complete
Tecentriq & Avastin Atezolizumab & Bevacizumab Hepatocellular Carcinoma (HCC) Reimburse with clinical criteria and/or conditions Complete